KBC Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

KBC Group’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-161	Closed	-$3K	–	1507
2019 Q2	$3K	Hold	161	–	–	﹤0.01%	1453
2019 Q1	$5K	Hold	161	–	–	﹤0.01%	1406
2018 Q4	$5K	Hold	161	–	–	﹤0.01%	1304
2018 Q3	$10K	Hold	161	–	–	﹤0.01%	1382
2018 Q2	$12K	Hold	161	–	–	﹤0.01%	1277
2018 Q1	$11K	Buy	+161	New	+$12.2K	﹤0.01%	1263

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

KBC Group's BLCM Position: Q3 2019 in Review

KBC Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2019, closing a stake of 161 shares — an estimated $3K sold.

KBC Group first reported a position in BLCM in Q1 2018 and held it in 6 quarters. The position peaked at $12K in Q2 2018. 67 funds tracked by Wall St. Rank hold BLCM as of Q3 2019.

KBC Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
KBC Group sold 161 Bellicum Pharmaceuticals, Inc. shares in Q3 2019, an estimated $3K.
KBC Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 6 quarters.
KBC Group's Bellicum Pharmaceuticals, Inc. position peaked at $12K in Q2 2018.
67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2019.

Based on KBC Group's 13F filing for Q3 2019, filed 7 Nov 2019.